Jodi Devlin joined TriSalus in August 2023 and serves as President, Therapeutics. Jodi has more than 30 years in the biotech and pharmaceutical industry. Her expertise includes prelaunch strategies, US and ex-US launches, medical affairs, marketing, sales, reimbursement, and patient advocacy. She has led multiple $B pharmaceutical launches.
At TriSalus, Jodi is leading the go-to-market strategy for SD-101. Her focus includes patient advocacy, medical affairs, health economics, and planning for commercial launch.
Prior to joining TriSalus, Jodi served as CEO of AltaThera Pharmaceuticals, a specialized, hospital pharmaceutical company. Jodi executed a turnaround where she raised funding, obtained a new FDA indication, built a commercial and clinical team, completed two new clinical trials, and significantly accelerated revenue. In addition, Jodi spent 21 years at Abbott/AbbVie where she held leadership roles in pipeline planning, global launches, and management of numerous commercial organizations. Jodi’s experience spans biotech start-ups and Fortune 500 companies. She currently serves as Chairman of the Board at Fitabeo Therapeutics.
Before her time in the biotech industry, Jodi worked as a hospital nurse in New York and Missouri. She earned a BS in Nursing from University of Oklahoma and a MBA from Washington University, Olin School of Business.